BAT Extends Partnership with McLaren F1 Team, Unveiling MCL38 Design by Japanese Artist

BAT by 2FIRSTS.ai
Apr.08.2024
BAT Extends Partnership with McLaren F1 Team, Unveiling MCL38 Design by Japanese Artist
British American Tobacco (BAT) partners with McLaren F1 team for 2024 F1 season, unveiling MCL38 with design by Japanese artist MILTZ.

According to the latest information on British American Tobacco (BAT) official website, the Formula One team McLaren used the F1 car "MCL38" with a design created by Japanese artist MILTZ during the 2024 F1 Japanese Grand Prix held in Tokyo from the 5th to the 7th. The "Driven by Change" project for this event was jointly developed by BAT's e-cigarette brand "Vuse" and the McLaren Formula One team.

 

BAT announced on April 8th that the company has signed a partnership agreement with the McLaren Racing team for the 2024 season and beyond. This deal means that BAT will continue to be the official main partner of the McLaren Formula One team for the 2024 season and beyond.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

PMI Launches Mass Production of ZYN at $600M Aurora Manufacturing Hub
PMI Launches Mass Production of ZYN at $600M Aurora Manufacturing Hub
Philip Morris International (PMI), through its subsidiary Swedish Match, has started large-scale production at a 600,000-square-foot ZYN nicotine pouch facility in Aurora, Colorado. The $600 million investment makes the site one of three ZYN manufacturing plants in the United States and the company’s second U.S. facility after Owensboro, Kentucky.
PMI
Feb.21
PMJ Expands SENTIA Tobacco Stick Lineup, Adds Blueberry Menthol Capsule Flavor
PMJ Expands SENTIA Tobacco Stick Lineup, Adds Blueberry Menthol Capsule Flavor
Philip Morris Japan (PMJ) announced that it will launch “SENTIA Purple Capsule,” the first capsule-equipped product in its SENTIA lineup dedicated to the heated tobacco “IQOS ILUMA” series, as an early release in Japan. The product will roll out nationwide starting from IQOS Stores, and will enter tobacco retail channels nationwide from April 6.
Mar.03 by 2FIRSTS.ai
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
After France’s ANSES report on nicotine products and harm reduction, Dr. Xin-an Liu wrote to 2Firsts reassessing the field’s foundations. She argues the debate reveals gaps in evidence on long-term behavioral substitution, addiction pathways and neurobiological impacts, and calls for longitudinal research, integrated behavioral science and neuroimaging, clearer risk assessment and stronger transparency to ensure policy and next-generation product development rest on solid evidence.
Industry Insight
Feb.24
South Korea’s finance ministry to directly crack down on illegal high-nicotine vape liquids
South Korea’s finance ministry to directly crack down on illegal high-nicotine vape liquids
The report says South Korea’s Ministry of Economy and Finance (referred to as the finance ministry) will directly lead crackdowns on illegal distribution and “upward manipulation” of nicotine concentrations in liquid e-cigarettes, after cases of extremely high-strength nicotine liquids circulating at retail shops were highlighted.
Feb.28 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
2Firsts|Sesh Advances Nicotine Pouch PMTA to Filing Stage, Experts Highlight Regulatory Threshold and Market Window
2Firsts|Sesh Advances Nicotine Pouch PMTA to Filing Stage, Experts Highlight Regulatory Threshold and Market Window
Sesh said its Premarket Tobacco Product Application (PMTA) for 64 nicotine pouch SKUs has been accepted by the U.S. Food and Drug Administration (FDA) and advanced to the Filing stage, entering substantive scientific review. Industry experts say the development signals that the application has crossed a key technical and regulatory threshold, while also highlighting growing divergence in regulatory capability and market positioning within the nicotine pouch category.
Special Report
Mar.24 by 2FIRSTS.ai